Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Breakthrough Cancer Detection Method Presentation

Tuesday, February 13, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Volition has presented a groundbreaking liquid biopsy blood test method for early cancer detection at ESMO 2023. This innovative approach aims to improve prognostic capabilities and potentially enhance patient outcomes. The announcement highlights the company's commitment to advancing cancer diagnostics through novel technologies.
Price reaction · baseline $21.8 (2024-02-13T15:55:00.000Z) · hit during market hours · 7 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-4.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of a new liquid biopsy blood test method.
  • Early detection of cancer could improve patient outcomes.
  • Presentation at a prominent event like ESMO 2023 enhances visibility.

Full Press Release Details

Volition introduces breakthrough data presented at ESMO 2023, regarding an entirely new liquid biopsy blood test method for the early detection of cancer.

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What was presented at ESMO 2023?

Volition introduced a new liquid biopsy blood test method for early cancer detection.

What is the significance of the new test?

The test aims to improve the early detection of cancer, potentially enhancing patient outcomes.

What is the Nu.Q cancer test?

The Nu.Q cancer test is related to the prognostic value of cancer detection methods.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Volition cancer detection liquid biopsy ESMO 2023 Nu.Q cancer test
Last updated: Feb 13, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk